Nancy J. Hutson - Nov 5, 2021 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc (PHASQ)

Role
Director
Signature
/s/ John P. Sharp, Attorney-in-fact
Stock symbol
PHASQ
Transactions as of
Nov 5, 2021
Transactions value $
$0
Form type
4
Date filed
11/8/2021, 05:26 PM
Previous filing
Nov 2, 2021
Next filing
May 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHASQ Common Stock Options Exercise $56.2K +24.9K $2.26* 24.9K Nov 5, 2021 Direct
transaction PHASQ Common Stock Options Exercise $4.73K +1.5K +6.03% $3.15* 26.4K Nov 5, 2021 Direct
transaction PHASQ Common Stock Options Exercise $23.3K +7.4K +28.07% $3.15* 33.8K Nov 8, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Non-employee Director Stock Option (right to buy) Options Exercise -$56.2K -24.9K -91.68% $2.26* 2.26K Nov 5, 2021 Common Stock 24.9K $2.26 Direct F1
transaction PHASQ Non-employee Director Stock Option (right to buy) Options Exercise -$4.73K -1.5K -16.85% $3.15* 7.4K Nov 5, 2021 Common Stock 1.5K $3.15 Direct F2
transaction PHASQ Non-employee Director Stock Option (right to buy) Options Exercise -$23.3K -7.4K -100% $3.15* 0 Nov 8, 2021 Common Stock 7.4K $3.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option shall vest with respect to 25% of the shares on February 21, 2019, and shall vest in 36 additional monthly installments thereafter, subject to the reporting person's continued service through each such date.
F2 The shares subject to the option shall vest in equal monthly installments over 36 months from October 17, 2018, subject to the reporting person's continued service through each such date.